Class information for:
Level 1: AGALACTOSYL IGG//PROT ANALYT CHEM//IGG GLYCOSYLATION

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
5664 1524 38.7 79%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1609 6531 FCRN//NEONATAL FC RECEPTOR//FC GAMMA RECEPTORS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 AGALACTOSYL IGG Author keyword 19 68% 1% 17
2 PROT ANALYT CHEM Address 18 38% 2% 37
3 IGG GLYCOSYLATION Author keyword 16 65% 1% 15
4 RECOMBINANT MONOCLONAL ANTIBODY Author keyword 16 54% 1% 20
5 MABS Journal 14 15% 6% 84
6 ANALYT FORMULAT SCI Address 12 40% 2% 23
7 PHARMA BIOTECH DEV PENZBERG Address 9 83% 0% 5
8 FAB ARM EXCHANGE Author keyword 9 67% 1% 8
9 CE SDS Author keyword 8 62% 1% 8
10 FC GLYCOSYLATION Author keyword 6 80% 0% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 AGALACTOSYL IGG 19 68% 1% 17 Search AGALACTOSYL+IGG Search AGALACTOSYL+IGG
2 IGG GLYCOSYLATION 16 65% 1% 15 Search IGG+GLYCOSYLATION Search IGG+GLYCOSYLATION
3 RECOMBINANT MONOCLONAL ANTIBODY 16 54% 1% 20 Search RECOMBINANT+MONOCLONAL+ANTIBODY Search RECOMBINANT+MONOCLONAL+ANTIBODY
4 FAB ARM EXCHANGE 9 67% 1% 8 Search FAB+ARM+EXCHANGE Search FAB+ARM+EXCHANGE
5 CE SDS 8 62% 1% 8 Search CE+SDS Search CE+SDS
6 FC GLYCOSYLATION 6 80% 0% 4 Search FC+GLYCOSYLATION Search FC+GLYCOSYLATION
7 IMMUNOGLOBULIN IGG2 6 100% 0% 4 Search IMMUNOGLOBULIN+IGG2 Search IMMUNOGLOBULIN+IGG2
8 ANTIBODY GLYCOSYLATION 5 55% 0% 6 Search ANTIBODY+GLYCOSYLATION Search ANTIBODY+GLYCOSYLATION
9 MICROFLUIDIC CD 4 67% 0% 4 Search MICROFLUIDIC+CD Search MICROFLUIDIC+CD
10 GALACTOSYLATION 4 22% 1% 17 Search GALACTOSYLATION Search GALACTOSYLATION

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SERUM IGG 48 41% 6% 90
2 AGALACTOSYL IGG 39 63% 3% 40
3 LOW FUCOSE IGG1 29 71% 2% 24
4 STRUCTURAL ISOFORMS 29 73% 1% 22
5 DEPENDENT CELLULAR CYTOTOXICITY 23 18% 8% 115
6 HUMAN IGG FC 23 60% 2% 25
7 EFFECTOR FUNCTIONS 22 17% 8% 118
8 IMMUNOGLOBULIN GAMMA ANTIBODIES 21 85% 1% 11
9 GALACTOSYLATION 20 36% 3% 45
10 THERAPEUTIC ANTIBODIES 20 24% 5% 74

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MABS 14 15% 6% 84

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Glycosylation as a strategy to improve antibody-based therapeutics 2009 246 66 62%
Characterization of Therapeutic Antibodies and Related Products 2013 64 210 46%
Terminal sugars of Fc glycans influence antibody effector functions of IgGs 2008 150 47 77%
Disulfide bond structures of IgG molecules Structural variations, chemical modifications and possible impacts to stability and biological function 2012 39 45 62%
Isotype and glycoform selection for antibody therapeutics 2012 49 114 51%
Emerging Principles for the Therapeutic Exploitation of Glycosylation 2014 48 86 16%
The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology 2015 2 114 32%
IgG glycosylation analysis 2009 96 193 49%
The impact of glycosylation on the biological function and structure of human immunoglobulins 2007 369 119 26%
IgG subclasses and allotypes: from structure to effector functions 2014 14 194 37%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PROT ANALYT CHEM 18 38% 2.4% 37
2 ANALYT FORMULAT SCI 12 40% 1.5% 23
3 PHARMA BIOTECH DEV PENZBERG 9 83% 0.3% 5
4 PROC PROD DEV 6 22% 1.7% 26
5 PROC SCI 5 18% 1.6% 25
6 LATE STAGE CELL CULTURE 4 33% 0.6% 9
7 OCEANSIDE PHARMA TECH DEV 3 43% 0.4% 6
8 PHARMA TECH DEV PENZBERG 3 100% 0.2% 3
9 PHARMACEUT LIFE SCI GRP 3 100% 0.2% 3
10 QUAL CONTROL CLIN DEV 3 60% 0.2% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000136777 PROTEIN FORMULATION//SUBVISIBLE PARTICLES//PROTEIN AGGREGATION
2 0.0000132402 DITHIONITROBENZOATE//IGG BLOOD//YOSHIDA HEPATOMA
3 0.0000111759 FCRN//NEONATAL FC RECEPTOR//TARGET MEDIATED DRUG DISPOSITION
4 0.0000108826 GLYCOPROTEOMICS//GLYCOMICS//GLYC GLYCOPROTE
5 0.0000106874 ASYMMETRIC ANTIBODIES//CA215//CARBOHYDRATE ASSOCIATED EPITOPE
6 0.0000103133 ISOASPARTATE//PROTEIN L ISOASPARTYL METHYLTRANSFERASE//DEAMIDATION
7 0.0000101286 CD20//OFATUMUMAB//OBINUTUZUMAB
8 0.0000091979 CHROMATOFOCUSING//ACID BASE RESIDUES//INDUCED PH GRADIENTS
9 0.0000082259 ANTIBODY DRUG CONJUGATE//ANTIBODY DRUG CONJUGATES//T DM1
10 0.0000076514 FC GAMMA RECEPTORS//FC RECEPTOR//FC GAMMA RIIA